AzurRx (AZRX) Corporate Media Kit

22 MS1819 Doses # Patients Safety Primary Efficacy Endpoints Secondary Efficacy Endpoints Status • 280 mg • 560 mg • 1120 mg • 2240mg 11 France, Aus, NZ • Statistically Significant 21.8% CFA improvement at highest dose of 2.2 g Statistically Significant and Clinically Meaningful • # bowel movements • stool consistency • steatorrhea Completed 2018 Baseline @ Highest Dose of MS1819-SD (2240 mg) Mean Change p-value Coefficient of Fat Absorption (CFA)* 41.2 63.3 21.8% 0.002 Stool Consistency (Bristol Scale) 5.1 4.1 -19.6% 0.006 Bowel Movements 2.8 1.9 -32% 0.006 Steatorrhea 12.3 10.1 -18% 0.008 Abdominal Discomfort (Visual Analog Scale) 21.0 14.5 -31% 0.148 MS1819 Phase 2 Chronic Pancreatitis Dose Escalation Study